Bethea ED, Chen Q, Hur C, et al. Cost-effectiveness of Treating Acute versus Chronic Hepatitis C Infection Using Direct-Acting Antivirals. AASLD 2017, abstract 24.
Perioperatief camrelizumab plus rivoceranib bij resectabel HCC met gemiddeld-hoog recidiefrisico
dec 2025 | Chirurgie, Maag-darm-leveroncologie